Immunotherapy failure in adrenocortical cancer: where next?

Immunotherapy is widely used in the treatment of different cancer types, including metastatic melanoma, non-small cell lung cancer, renal cell carcinoma and urothelial cancer. The results of the phase I JAVELIN study failed to demonstrate a substantial activity of the PDL-1 inhibitor Avelumab in adv...

Descripción completa

Detalles Bibliográficos
Autores principales: Cosentini, Deborah, Grisanti, Salvatore, Dalla Volta, Alberto, Laganà, Marta, Fiorentini, Chiara, Perotti, Paola, Sigala, Sandra, Berruti, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2018
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280582/
https://www.ncbi.nlm.nih.gov/pubmed/30400026
http://dx.doi.org/10.1530/EC-18-0398
_version_ 1783378710287613952
author Cosentini, Deborah
Grisanti, Salvatore
Dalla Volta, Alberto
Laganà, Marta
Fiorentini, Chiara
Perotti, Paola
Sigala, Sandra
Berruti, Alfredo
author_facet Cosentini, Deborah
Grisanti, Salvatore
Dalla Volta, Alberto
Laganà, Marta
Fiorentini, Chiara
Perotti, Paola
Sigala, Sandra
Berruti, Alfredo
author_sort Cosentini, Deborah
collection PubMed
description Immunotherapy is widely used in the treatment of different cancer types, including metastatic melanoma, non-small cell lung cancer, renal cell carcinoma and urothelial cancer. The results of the phase I JAVELIN study failed to demonstrate a substantial activity of the PDL-1 inhibitor Avelumab in advanced adrenocortical carcinoma (ACC). This editorial focus on the possible mechanisms of ACC immunoevasion and suggests strategies to overcome the intrinsic immunotherapy resistance of this disease.
format Online
Article
Text
id pubmed-6280582
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-62805822018-12-10 Immunotherapy failure in adrenocortical cancer: where next? Cosentini, Deborah Grisanti, Salvatore Dalla Volta, Alberto Laganà, Marta Fiorentini, Chiara Perotti, Paola Sigala, Sandra Berruti, Alfredo Endocr Connect Editorial Immunotherapy is widely used in the treatment of different cancer types, including metastatic melanoma, non-small cell lung cancer, renal cell carcinoma and urothelial cancer. The results of the phase I JAVELIN study failed to demonstrate a substantial activity of the PDL-1 inhibitor Avelumab in advanced adrenocortical carcinoma (ACC). This editorial focus on the possible mechanisms of ACC immunoevasion and suggests strategies to overcome the intrinsic immunotherapy resistance of this disease. Bioscientifica Ltd 2018-10-30 /pmc/articles/PMC6280582/ /pubmed/30400026 http://dx.doi.org/10.1530/EC-18-0398 Text en © 2018 The authors http://creativecommons.org/licenses/by-nc/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Editorial
Cosentini, Deborah
Grisanti, Salvatore
Dalla Volta, Alberto
Laganà, Marta
Fiorentini, Chiara
Perotti, Paola
Sigala, Sandra
Berruti, Alfredo
Immunotherapy failure in adrenocortical cancer: where next?
title Immunotherapy failure in adrenocortical cancer: where next?
title_full Immunotherapy failure in adrenocortical cancer: where next?
title_fullStr Immunotherapy failure in adrenocortical cancer: where next?
title_full_unstemmed Immunotherapy failure in adrenocortical cancer: where next?
title_short Immunotherapy failure in adrenocortical cancer: where next?
title_sort immunotherapy failure in adrenocortical cancer: where next?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280582/
https://www.ncbi.nlm.nih.gov/pubmed/30400026
http://dx.doi.org/10.1530/EC-18-0398
work_keys_str_mv AT cosentinideborah immunotherapyfailureinadrenocorticalcancerwherenext
AT grisantisalvatore immunotherapyfailureinadrenocorticalcancerwherenext
AT dallavoltaalberto immunotherapyfailureinadrenocorticalcancerwherenext
AT laganamarta immunotherapyfailureinadrenocorticalcancerwherenext
AT fiorentinichiara immunotherapyfailureinadrenocorticalcancerwherenext
AT perottipaola immunotherapyfailureinadrenocorticalcancerwherenext
AT sigalasandra immunotherapyfailureinadrenocorticalcancerwherenext
AT berrutialfredo immunotherapyfailureinadrenocorticalcancerwherenext

Ejemplares similares